Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Neoadjuvant chemotherapy may improve overall survival (OS) in 'borderline' resectable pancreatic cancer (RPC). Whether the results are the same in upfront RPC is unknown.

Materials and methods

To evaluate the association of neoadjuvant treatment and survival outcomes in RPC, a systematic literature review was carried out including prospective randomized trials of neoadjuvant treatment versus upfront surgery. Articles indexed in PubMed, Embase and Scopus were evaluated. Data regarding systemic treatment regimens, R0 resection rates, disease-free survival (DFS) and OS were extracted. The outcomes were compared using a random-effects model. The index I² and the graphs of funnel plot were used for the interpretation of the data.

Results

Of 3229 abstr

SUBMITTER: Uson Junior PLS 

PROVIDER: S-EPMC10024142 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature